Objective: To explore predictors of programme adherence and weight loss in patients participating in a weight management programme using meal replacements (MR).
INTRODUCTION
There are two aspects that may be considered as relevant to the success of a weight reduction programme: continued adherence to the programme and the extent of weight loss among those who continue. However, there are few biological predictors known to predict these outcomes. Accurate or sensitive predictors would be useful in selecting an appropriate treatment regimen for individual obese patients. Earlier studies suggest that a positive family history [1] , repeated weight loss in the past and extreme body dissatisfaction were important factors in predicting weight loss [2] . Higher pre-treatment body weight, [3] resting metabolic rate (RMR), fat cell hyperplasia and upper body fat distribution [4] were associated with greater weight losses.
Recently a trial of diet and pharmacotherapy showed positive associations of weight loss at 6 months with pre-treatment body weight, height, fat-free mass, fat mass and resting metabolic rate [5] . Other factors implicated as predictors include a low ratio of fat to carbohydrate oxidation [6] , high basal 24-hour energy expenditure, plasma noradrenaline and androgens [7] .
Hyperinsulinemia, hypertension and insulin resistance are frequently observed in obesity.
The relationship between hyperinsulinemia, insulin resistance and weight change is not straightforward. Previous studies have yielded conflicting results. While the CARDIA (Coronary Artery Risk Development in Young Adults) study showed a positive association between fasting insulin and weight gain, the ARIC (Atherosclerosis Risk in Communities) study showed a lower rate of weight gain with greater fasting hyperinsulinemia [3, 8] . Odeleye et al found that greater insulin resistance predicts weight gain [9] whereas Swinburn et al found that the greater the insulin resistance, measured by glucose disposal rates, the lower the risk of weight gain in obese nondiabetic Pima Indians [10] . Conversely, Schwartz et al, found that relative hypoinsulinemia independently predicted weight gain [11] . Other studies have shown no correlation between fasting insulin and weight gain [12] . Most of these studies were observational retrospective analyses without any intervention. McLaughlin et al explored insulin sensitivity as a weight loss predictor, by measuring insulin mediated glucose disposal using steady state plasma glucose in 20 obese female subjects on a hypocaloric diet. Insulin resistance did not predict weight loss in this setting [13] .
The aim of this study was to explore predictors (in particular initial insulin resistance) of programme adherence and weight loss and weight loss maintenance in patients participating in a weight management programme using meal replacements.
METHODS

Phase 1-Weight Loss Phase
During this phase, subjects were provided free a 900-calorie/ day diet consisting of 2 SlimFast Meal Replacements ™ (SFMR) each providing 200 calories, and one low fat meal of 300 calories; in addition patients were allowed 3 items of fruit and 2 servings of vegetables. Subjects attended biweekly for a one-hour dietetic and cognitive behavioural therapy (CBT) session delivered by a dietician with special skills in CBT. Monthly medical checks were carried out.
Initially only subjects who achieved ≥10% weight loss after 16 weeks entered Phase 2. This was based on a 75% compliance with a theoretical calculation of weight loss based on the expected caloric deficit. However, on compassionate grounds a protocol amendment was made to allow a further 13 women who achieved at least 9% but less than 10% weight loss to be admitted to Phase 2.
Phase 2 -Weight Loss Maintenance
During this phase, subjects were given a weight maintenance regimen including group dietetic and lifestyle therapy, behavioural modification and advice on increased physical activity based on the CHANGE programme [14] . Dietary advice was modified to allow the use of at least 10 SlimFast ready-made liquid or powder meal replacements each week. The limited use of two meal replacements per day was permitted in patients tackling temporary relapse (no more than two weeks in any eight week period). Patients were asked to return used Slim-Fast tin lids, which were recorded to assess compliance. New tins were dispensed according to participants' usage of the diet supplement and the numbers of lids returned.
Subjects continued to attend the Research Centre for weighing monthly, and for group therapy sessions monthly, for the first six months, bi-monthly, for the next six months, and were planned to attend quarterly for the second year.
These data relate to the 16 weeks of Phase 1 and the first year of the weight loss management (WLM) phase. The study was terminated after the first year of the WLM phase because of the high attrition rate.
Subjects and Methods
188 healthy, obese women aged between 35 and 65 with a BMI range of 30 to 45 were screened through advertisements in local news media. Subjects were excluded if they were dieting, had a secondary cause of obesity, were on drugs known to affect energy balance, had a history of eating disorder, had lactose intolerance or if they had significant co-morbidity (uncontrolled hypertension, recent myocardial infarction, recent CABG, diabetes requiring insulin, gallstones, chronic illness or malignancy). This left 150 subjects who took part in the trial. The local Research Ethics Committee approved the study and all subjects gave informed written consent prior to participation.
Weight: was taken with the patient in light clothing and bare feet on Tanita (310) body composition analyser, calibrated to the nearest 0.1 kg.
Height: was taken by standing the subject against a wall-mounted stadiometer and to the nearest 0.5 cm Body Mass Index (BMI): was calculated as weight in kg divided by the square of the height in metres.
Waist Circumference (WC): was measured according to the WHO criteria. It was taken at the midpoint between the lowest point of the costal margin and the highest point of the anterior superior iliac spine.
Hip circumference (HC): was taken at the level of the greater trochanters bilaterally with the tape measure passing round the widest part of the buttock and the symphysis pubis.
Body Composition: was measured using air plethysmography on the principle of air displacement [15] . Whole body density is measured and from this the relative proportion of fat and lean body mass is calculated using standard equations. The procedure has been shown to be safe, quick, noninvasive, accurate and reproducible [16] .
Laboratory Measurements
All samples were taken after a 10-hour overnight fast. Glucose: was measured by the glucose oxidase method. Insulin was estimated using Microparticle Enzyme Immunoassay. The cross reactivity with proinsulin is negligible (<0.005). The sensitivity is 0.03 µIU/ml. The co-efficient of variation (CV) for intra-assay, inter-assay and total precision is 3.1%, 3.8% and 5% respectively.
Insulin sensitivity was assessed using the mathematical model devised by Matthews et al. with the formula: insulin resistance = (fasting insulin x fasting glucose) ÷ 22.5 [17] . Patients were further classified according to whether or not they met the ATPIII criteria for metabolic syndrome [18] .
Statistical Analyses
Data were analysed using SPSS version 11. Logs to the base 'e' were taken of the HOMA-IR and HOMA-IS measures before statistical analysis to correct for the skewed distributions of the raw values. Summary statistics are expressed as means (sd), Pearson correlations, percentages or odds ratios. Confidence intervals are 95% and are shown as (lower limit to upper limit).
T-tests and Mann-Whitney non-parametric tests were used to test differences between groups. Multi-level models were used to estimate mean rates of weight loss. Ordinal logistic regression and Cox Survival Analysis were used to explain continued adherence and weight loss in terms of various measures. p-values refer to two-sided tests.
RESULTS
Descriptive Statistics
The physical and demographic characteristics of the 150 subjects on entering Phase 1 are shown in Table 1 , and a CONSORT description of the progress of subjects through the study is in Of the 114 who completed Phase 1, not all had complete Phase 1 physiological measurements.
Since patients did not always know prior to attendance that they might have achieved the target loss to proceed to Phase 2, it was sometimes necessary for them to return fasting within 1-2 days for blood samples or body composition. The numbers of subjects for each measure, and the changes, are shown in Table 2 . The baseline values for the women with incomplete data did not differ from those of the women with complete data.
Forty-six (66%) of the 70 participants who entered the weight loss maintenance phase, Phase 2, completed the phase to its end at 12 months. They experienced an overall regain of total body weight, BMI, absolute fat mass, waist circumference, cholesterol and HDL-C. Although reaching statistical significance, these increases over Phase 2 were small compared to the decreases achieved over Phase 1. The overall levels observed at the end of Phase 2 continued to be lower than at baseline. During Phase 2 HOMA-IR decreased and HOMA-IS increased although both were 50% below baseline levels at the end of Phase 2. There were no statistically significant changes in lean body mass, plasma glucose, LDL-C and fasting triglyceride during Phase 2.
The dropout rates were 24% and 34% over Phase 1 and Phase 2 respectively. The main reasons given were work and family commitments. Five subjects had to be withdrawn at the end of Phase 1 for medical reasons.
What Predicts Continued Participation ?
There was a pattern of trend to earlier drop-out with younger age and higher values for HOMA, WHR, waist circumference and bodpod fat although when considered one at a time none of these measures reached statistical significance. However, a linear logistic ordinal regression showed that, in combination, older age, smaller waist and higher BMI at baseline predicted probability of continuation beyond 10 weeks or beyond 16 weeks (p=0.022). (See Table 3 ).
Cox survival analysis found that, in Phase 1, continuation in the study was in part predictable from weight loss over the first two weeks. Greater weight loss measured at week two related to longer continuation in the trial. (p<0.001). See Fig 2 where weight loss after two weeks is categorised into tertiles.
What Predicts Weight Loss ?
Mean weight at various stages of the study is described by the line graphs in Figure 3 . Since the intervention represents a fixed energy intake of 900 cals per day, it is to be expected that heavier subjects will experience a larger deficit and hence lose more weight. This was confirmed by correlation of weight at week 0 to weight loss at week 16 of 0.422 (p<0.001). Clearly initial weight predicts weight loss through Phase 1. As a consequence, any measure which is correlated with initial weight will also appear to predict weight loss. To examine the extent to which other measures predict weight loss independently of their association with initial weight it was therefore necessary to partial out initial weight from their correlations with weight loss. Table 4 
DISCUSSION
This study set out to explore physiological predictors of continued study participation and weight loss in the study participants including the role of insulin sensitivity in prediciting weight loss. Since patients who demonstrated a greater weight loss after two weeks of participation in the trial were more likely to continue in the trial it may be assumed that those who did not continue to participate were not successful in losing weight. Hence continuation of participation is of prime importance and progress during the first two weeks should be given particular attention in future trial designs.
The contribution of body shape (smaller waist, higher BMI) and age (but not metabolic variables such as insulin resistance or secretion) to continued participation suggests a psychological dimension which should be the subject of further research.
The attrition rate in this study was higher than expected, and similar rates have been reported in previous studies with meal replacements. The reasons for this are not immediately obvious. The study was conducted on patients attending as out-patients within the setting of the UK National Health Service. Patients received no covert or overt incentives to remain on the programme other than the initial provision of the meal replacements. However drop-out rates in obesity trials are high. A trial using 16 weeks of VLCD followed by intermittent or on demand periods of VLCD showed only 35% of patients completed two years [19] . A randomised controlled trial of four commercial weight loss programmes in a community based sample of obese adults was conducted by the British Broadcasting Corporation under scientific supervision. It recruited 293 subjects (the largest such study in the UK) and reported a drop-out rate of 28% at six months [20] . A recent trial of dietary therapy in the US, also showed comparable drop-out rates after one year: 39 percent of participants on an Atkins-type diet dropped out compared with 43 percent of those on the conventional diet [21] . Even in drug trials where there is an apparent greater and more medicalised intervention, drop-out rates are high. For example in a one year trial of diet with orlistat or placebo in the UK, the drop-out rate was 48% in the placebo group and 39% in the orlistat group [22] . The relatively small numbers completing Phase 2 represented a limitation to the power of this part of the analysis. In looking at weight loss to the end of Phase 2 a sample correlation had to be at least 0.29 to qualify for statistical significance.
In keeping with earlier studies, baseline weight predicted weight loss [5, 23, 24] . Other predictors include baseline BMI, age, sex and hormonal and metabolic variables like RMR, fat oxidation, plasma dihydrotestosterone and plasma noradrenaline [7] . followed up patients without a therapeutic programme. Thus the effect of insulin on weight gain was explored extensively, unlike the present study which has looked at the effect of insulin and insulin resistance on weight loss. Secondly, the methods used for assessing insulin sensitivity were differrent in the various studies. Two of the studies employed the euglycemic hyperinsulinemic clamp techniques [10, 25] , one used the isotope dilution method for glucose disposal and the last used only the fasting insulin as a surrogate measure of insulin resistance [26] . In the study by Sigal et al, hyperinsulinemia estimated by the acute insulin response to intravenous glucose predicted weight gain while fasting insulin in the same study showed no correlation. Thirdly, the differences could be explained by the different ethnic population groups and sample sizes. These involved Pima Indians, Hispanic and non-Hispanic whites, Europeans and offspring of Type 2 diabetic parents, adults and children.
A new finding in this study is that systolic blood pressure and cholesterol were predictors of initial weight loss and weight loss maintenance at 1 year, respectively. The relationship between these baseline characteristics and weight loss were significant even after adjusting for baseline weight suggesting an independent mechanism. It is recognized that blood pressure is related to weight gain, glucose intolerance and insulin resistance [27] . Many studies have suggested that insulin resistance is the metabolic link between obesity and hypertension [28] . In this study, while blood pressure predicted weight loss, insulin resistance did not predict weight loss. Patients were unaware of their biochemistry results, so it does not seem likely that knowledge of blood pressure or cholesterol would have lead to improved dietary compliance.
In conclusion, this study showed that 76% of patients achieved a mean weight loss of 9% within 16 weeks using of a meal replacement diet programme. A minority of patients continued on a weight maintenance diet and behaviour programme for one year, but those that continued in therapy maintained much of their loss. It remains the challenge for obesity treatment to find ways of improving the retention of patients in treatment, and that this is perhaps a more important target than increased weight loss itself. * mean of screening and week 0 weights used for this † Glucose and Cholesterol did not correlate with initial weight hence their correlations were not adjusted for this.
